Charles River Laboratories
$ 189.85
1.83%
09 Jun - close price
- Market Cap 8,980,391,000 USD
- Current Price $ 189.85
- High / Low $ 193.17 / 184.53
- Stock P/E N/A
- Book Value 61.05
- EPS -3.71
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE -0.06 %
- 52 Week High 228.88
- 52 Week Low 143.06
About
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
Analyst Target Price
$212.27
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-18 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-19 | 2024-11-06 | 2024-08-07 | 2024-05-09 | 2024-02-14 | 2023-11-08 | 2023-08-09 |
| Reported EPS | -0.3 | 2.39 | 2.43 | 3.12 | 2.34 | 2.66 | 2.59 | 2.8 | 2.27 | 2.46 | 2.72 | 2.69 |
| Estimated EPS | 0.91 | 2.35 | 2.34 | 2.55 | 2.07 | 2.53 | 2.42 | 2.39 | 2.06 | 2.4 | 2.37 | 2.64 |
| Surprise | -1.21 | 0.04 | 0.09 | 0.57 | 0.27 | 0.13 | 0.17 | 0.41 | 0.21 | 0.06 | 0.35 | 0.05 |
| Surprise Percentage | -132.967% | 1.7021% | 3.8462% | 22.3529% | 13.0435% | 5.1383% | 7.0248% | 17.1548% | 10.1942% | 2.5% | 14.7679% | 1.8939% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 2.73 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRL
2026-06-09 16:37:21
Charles River Laboratories (CRL) has seen its shares recover recently, though they remain down year-to-date. The article presents conflicting valuation signals, with one community narrative suggesting the stock is 40.6% undervalued at $313.61 due to expected revenue expansion and profit margin improvement. However, Simply Wall St's DCF model indicates CRL is currently overvalued, trading at $186.44 against an estimated fair value of $78.47, implying significant optimism is already priced in.
2026-06-09 16:31:25
Charles River Laboratories (CRL) has seen its share price recover recently, despite being down year-to-date. While one narrative suggests the stock is significantly undervalued with a fair value of $313.61, a discounted cash flow (DCF) model presents a tougher picture, valuing CRL at $78.47. The article highlights the conflicting valuations and encourages investors to examine the underlying assumptions and risks.
2026-06-09 08:59:21
Barclays analysts have provided insights into several healthcare companies. Luke Sergott maintained a Buy rating for Charles River Labs (CRL) with an $220.00 price target, while Etzer Darout maintained a Buy rating for Incyte (INCY) with a $117.00 price target. Conversely, Emily Field issued a Sell rating for Pfizer (PFE) with a $25.00 price target.
2026-06-09 08:37:25
This article provides analyst insights on three healthcare companies: Charles River Labs (CRL), Incyte (INCY), and Pfizer (PFE). Barclays analysts maintained a Buy rating for Charles River Labs and Incyte with price targets of $220.00 and $117.00 respectively, while maintaining a Sell rating for Pfizer with a price target of $25.00. The article details the specific analyst ratings, price targets, and consensus ratings for each company from various financial institutions.
2026-06-08 20:37:18
Charles River Laboratories executive Shannon M. Parisotto reported non-market movements of common stock, including bona fide gifts totaling 3,058 shares on June 5, 2026. These transactions, which also included an exempt transfer to a revocable trust, were not open-market purchases or sales. Following these movements, Parisotto's holdings include 9,853 direct shares, 9,680 shares indirectly through a trust, and 28,510 shares indirectly via Karpathos Investments LLC.
2026-06-08 20:25:25
Charles River Laboratories (NYSE: CRL) director James C. Foster reported exempt, bona fide gifts and trust transfers totaling 366,722 shares of common stock on June 5, 2026. These transactions, valued at $0.00 per share, involved movements between his direct holdings, revocable trusts he controls, and trusts associated with his spouse, not open-market sales or purchases. Following these transfers, Foster holds 126,596 shares directly and significant indirect holdings through various trusts and GRATs.
